CS
ROSG

Credit Suisse’s Rosetta Genomics Ltd. ROSG Stock Holding History

Credit Suisse’s Portfolio ROSG Stock Details ROSG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,409
Closed -$204K – 4916
2014
Q1 		$204K Buy
+3,409
New +$176K ﹤0.01% 4345

Other funds holding ROSG

BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
HCM
Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's ROSG Position: Q2 2014 in Review

Credit Suisse sold out of Rosetta Genomics Ltd. (ROSG) in Q2 2014, closing a stake of 3,409 shares — an estimated $204K sold.

Credit Suisse first reported a position in ROSG in Q1 2014 and held it in 1 quarter. The position peaked at $204K in Q1 2014. 16 funds tracked by Wall St. Rank hold ROSG as of Q2 2014.

  • Credit Suisse reported no remaining Rosetta Genomics Ltd. position as of Q2 2014 after selling out during the quarter.
  • Credit Suisse sold 3,409 Rosetta Genomics Ltd. shares in Q2 2014, an estimated $204K.
  • Credit Suisse first reported a position in Rosetta Genomics Ltd. in Q1 2014 and held it in 1 quarter.
  • Credit Suisse's Rosetta Genomics Ltd. position peaked at $204K in Q1 2014.
  • 16 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q2 2014.

Based on Credit Suisse's 13F filing for Q2 2014, filed 11 Aug 2014.